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CYP2C19*2(GA) carries is a statistically non significant with basal aggregation, be-
fore PCI, day after PCI, and after PCI, while significant with inhibition percentage
before PCI.CONCLUSIONS: Therewas a variable individual response to Clopidogrel
between patients carries CYP2C19*1.CYP2C19*2 (GA) genotype and carries
CYP2C19*1.CYP2C19*1 (GG) genotype.
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OBJECTIVES: This study examined VTE prophylaxis and VTE risk reduction and
readmission in a cohort of hospitalized medically ill patients in the real-world
clinical setting during hospitalization and post discharge. METHODS: This 5-year
retrospective study used linked outpatient files from MarketScan® Commercial
and Medicare Supplemental databases, thereby providing continuity of therapy
through hospitalization and post-discharge. Patients were categorized into pro-
phylaxis and non-prophylaxis groups based on use of any guideline-recommended
anticoagulants from the index date to 180 days after index hospital discharge, and
before the date of the first VTE event. Outcome variables were VTE events and
re-hospitalization. Risk adjustment was conducted within the prophylaxis group,
and between the prophylaxis and non-prophylaxis groups using propensity score
matching. RESULTS: Among 3916 patients identified, 29.37% (n1295) were admit-
ted with cancer, 18.25% (n805) with pneumonia, 14.24% (n628) with heart fail-
ure, 11.25% (n496) with sepsis, 8.19% (n361) with infectious diseases, 5.67%
(n250) with severe respiratory disorders, and 1.84% (n81) with inflammatory
bowel disease (IBD). Among these patients, only 1819 (51.81%) received anticoagu-
lant therapy and 242 (6.18%) received non-pharmacological prophylaxis only dur-
ing their hospitalization and until 180 days after discharge. The anticoagulant
therapy rates ranged from 88.64% in obesity to 32.39% in IBD patients. Among
patients who received anticoagulant therapy, 740 (40.68%) received low molecular
weight heparin only and 806 (44.31%) received unfractionated heparin. After risk
adjustment, compared to patients without VTE prophylaxis, those patients who
received anticoagulant prophylaxis had lower VTE rates (3.62% vs. 4.27%., p0.04)
and lower readmission rates (24.22% vs 27.95%, p0.02) during the 6-month period
from the index hospital admission. CONCLUSIONS: Despite existing guidelines,
anticoagulant prophylaxis is underutilized inmedically ill patients in clinical prac-
tice. Anticoagulant prophylaxis is associated with reduced risk of VTE and rehos-
pitalization in medically ill patients.
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OBJECTIVES: The association of antihypertensive medication adherence with oc-
currence of complications and all-cause medical costs was examined using data
from the Health Insurance Review and Assessment Service(HIRA).METHODS: This
studywas a retrospective analysis of HIRA administrative claims data from January
2005 to December 2009. All subjects initiating therapy with oral antihypertensive
drugs were identified in January through December 2006. The index date was the
date of the first hypertension-related prescription. Patients were observed for 1
year before and 3 years after therapy initiation. Outcomes included occurrence of
complications and all-cause medical costs; occurrence of complications was mea-
sured starting 2 years after therapy initiation through follow-up and all-causemed-
ical costsweremeasured all durations of follow-up. Adherencewasmeasuredwith
a medication possession ratio (MPR) and categorized 19%, 20-39%, 40-59%, 60-
79%, and 80%. Using Cox survival regression, Occurrence of complications was
modeled at levels of MPR. All-cause medical costs were modeled with generalized
linear model regression. RESULTS: Average MPR in the total of 290,602 hyperten-
sion patients was 82.8%(21.2). In Cox survival analysis, risk of complications in-
creased as levels of MPR decreased. Patients with the lowest MPR level versus
optimal adherence had 3 times higher risk of complications (hazard ratio3.00,
95%CI2.69-3.35). Under the adjustmentwith covariates, annual all-causemedical
costs per patient were 23% higher for patients with the lowest MPR level versus
optimal level (exponential coefficient1.23, 95% CI1.20-1.25). The costs, however,
were 2-7% lower for groups with MPR 20-39%, 40-59% and 60-79%, because phar-
macy costs offset in/out-patient care cost saving. CONCLUSIONS: This study
showed strong associations between decreased antihypertensive medication ad-
herence and increased risk of complication occurrence. And the lowest adherence
was associated with higher all-cause medical costs. Further research is needed in
longer than 3 year follow-ups to assess the economic impact of adherence.
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OBJECTIVES: To compare baseline characteristics and dosage patterns among Jap-
anese patients newly started on statin. METHODS: Patients 18 years were iden-
tified between June 2006 to August 2010, with a minimum 6-month pre- and 12-
month post-index health plan eligibility from the Japan Medical Data Center
Database. A 90-day statin-free washout period was applied to identify patients in
whom statin therapywas newly prescribed. The index datewas defined as the date
of the first statin prescription. Five cohorts were created based on index statins
[atorvastatin (ATS), simvastatin (SIS), rosuvastatin (ROS), pitavastatin (PTA), and
pravastatin (PRS)] comparing demographics, comorbidities, statin dosage patterns,
prior medication, health care costs and resource utilization. RESULTS: There were
14,675 patients identified across 5 cohorts: 27.7% ATS, 6.4% SIS, 26.9% ROS, 12.9%
PTA and 26.0% PRS. PTA cohort had more diabetes (PTA 14.0% vs. ATS 10.2%, SIS
6.5%, ROS 12.8%, PRS 9.6%) and coronary artery diseases (PTA 8.6% vs. ATS 7.7%, SIS
4.1%, ROS 7.4%, PRS 7.3%). ROS cohort had more prior peripheral vascular disease
(ROS 6.6% vs. ATS 5.6%, SIS 3.6%, PTA 5.6%, PRS 5.5%), cerebrovascular disease (ROS
7.0% vs. ATS 6.6%, SIS 2.9%, PTA 5.7%, PRS 6.3%), and hypertension (ROS 33.2% vs.
ATS 30.2%, SIS 27.4%, PTA 30.9%, PRS 30.2%). SIS cohort hadmore prior outpatients
visits (SIS 9.6 vs. ATS 8.2, ROS 8.7, PTA 8.2, PRS 9.3). Prior healthcare costs were
similar across 5 cohorts. Majority of patients were prescribed lower statin doses:
ATS, 10mg (60%); SIS, 5mg (86%); ROS, 2.5mg (89%); PTA, 1mg (49%); PRS, 10mg
(62%).CONCLUSIONS: Japanese patients newly started on a statin had similar prior
health care costs, andwere prescribed lower doses compared toWestern countries.
Patients with diabetes and coronary artery diseases were more likely to be pre-
scribed PTA.
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OBJECTIVES: To describe demographics, treatment patterns and outcomes of pa-
tients with pulmonary arterial hypertension (PAH) and chronic thromboembolic
pulmonary hypertension (CTEPH) treated under everyday practice.METHODS: Ret-
rospective chart review of PAH (N285) and CTEPH (N120) patients treated with
endothelin receptor antagonists, prostacyclin analogues or PDE-5 inhibitors be-
tween July 2003 and June 2009 in specialized centers in 6 countries (France, Ger-
many, Italy, Spain, Sweden, and United Kingdom). Data were extracted from pa-
tient files and analyzed descriptively. For survival analysis, Kaplan-Meier
estimates were used. RESULTS: PAH patients (idiopathic 49.8%, mean age
55.315.6 years, 74.4% females, 6-min-walk-distance [6-MWD] 328121 meters,
NYHA class II/III/IV in 20/66/14%) and CTEPH patients (83.7% inoperable and 15.8%
persistent after surgery, 67.512.1 years, 60.0% females, 6-MWD 298120 meters,
NYHA II/III/IV in 27/58/15%). Mean pulmonary arterial pressure was 5016 mmHg
in PAH and 4511 mmHg in CTEPH. Mean pulmonary vascular resistance was
939760 dyn*s*cm-5 in PAH and 797726dyn*s*cm-5 in CTEPH. At baseline, 93.7%
PAH patients received monotherapy (bosentan 47.0%, sildenafil 35.8%), with con-
comitant diuretics (40.0%) and anticoagulants (30.2%). CTEPH patients received
monotherapy in 99.2% (bosentan 56.7%, sildenafil 34.8%), with concomitant diuret-
ics (59.2%) and anticoagulants (62.5%). Mean observation time was 2.2 years (PAH)
and 2.1 years (CTEPH). At end of observation, in the PAH group mean 6-MWD
increased by 3291 meters and by 3090 in the CTEPH group. In the PAH group,
29.1% of patients improved, 63.8%were unchanged, 7.1% deteriorated in the NYHA
class, and 20.4% died (annualized death rate 10.3%); in the CTEPH group 32.2%
improved, 59.3% were unchanged, 8.5% deteriorated, and 13.3% died (annualized
death rate 6.4%). CONCLUSIONS: These data reflect real-life treatment patterns in
PAH and CTEPH patients in a period when several new PAH-specific treatments
were introduced. Overall, drug utilization was similar in PAH and CTEPH patients
(although off-label in the latter group). In viewof outcomes there still a great unmet
need, especially for patients with CTEPH.
PCV23
PREVALENCE AND INCIDENCE OF ATRIAL FIBRILLATION: AN ANALYSIS BASED
ON 8.3 MILLION PATIENTS
Wilke T1, Groth A2, Mueller S2, Verheyen F3, Linder R3, Pfannkuche M4, Maywald U5,
Bauersachs R6, Breithardt G7
1Hochschule Wismar, Wismar, Germany, 2IPAM Wismar, Wismar, Germany, 3Scientific Institute
of Techniker Krankenkasse for Benefit and Efficiency in Health Care, Hamburg, Germany,
4Boeringer Ingelheim Pharma GmbH & Co.KG, Ingelheim, Germany, 5AOK Plus, Dresden,
Germany, 6Klinikum Darmstadt GmbH, Darmstadt, Germany, 7University Clinic Muenster,
Muenster, Germany
OBJECTIVES: The aims of this contribution are to update andmore precisely quan-
tify the age and gender-specific prevalence and incidence of atrial fibrillation (AF)
in an European setting (Germany).METHODS:To fulfill the aims of the study, it was
decided to make a population-based analysis of the claims data collected by a
statutory health insurance fund, and concerning its 8.298 million members. A pa-
tient was classified as AF prevalent if he/she had received at least two outpatient
diagnoses of AF (ICD10-Code I48.1) in two different quarters of the year and/or had
received at least one main AF diagnosis during inpatient treatment between Janu-
ary 1, 2007 andDecember 31, 2008. A patientwas considered to have had new onset
AF in 2008 under one of three conditions; firstly, he/she had not received a diagno-
sis of AF in 2007; secondly, had not received oral anticoagulant medication in 2007;
and thirdly, had received either one inpatient AF diagnosis in 2008, or two such
outpatient diagnosis made in different quarters of that year. AF prevalence is re-
ported in %, AF incidence is reported as cases per 1000 person-years. RESULTS: In
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our sample, a total of 176,891 patients hadAF. By reference to the totalmembership
of the twomedical insurance funds, the prevalence of AFwas 2.132% (men: 2.369%;
women: 1.895%). The average age of these AF patients was 73.1 years, and 55.5%
(98,190 patients) were male. The incidence of AF in our sample was 4358 cases per
1000 person-years in men and 3.868 cases in 1000 person-years in women. AF
prevalence/incidence clearly depends on age and gender. CONCLUSIONS: A com-
parison of the distribution of AF prevalence/incidence in our population with that
in already published studies shows that our figures are higher, especially in the age
groups above 70 years. Obviously, AF prevalence/incidence are further increasing
in industrialized countries.
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OBJECTIVES: In this study we performed congestive heart failure (CHF) gap analy-
sis for the residents of Lake county, IL based on the hospital discharge data col-
lected between 2001- 2009.METHODS: The hospital discharge data between 2001-
2009 for primary diagnosis of CHFwas analyzed. All patients ( 4 yr to 85yr) were
categorized in 10 age groups and comparative analysis was performed. Patient
cases for systolic and diastolic CHF were identified using ICD-9 codes for systolic
and diastolic heart failures.RESULTS:N 827,355 discharge recordswere screened.
Overall therewereN15299 cases thatwere dischargedwith the primary diagnosis
of systolic CHF reflecting a crude rate of 1.8 %. The reported rate by the AHQR for
state of IL in 2006 was 501.9/ 2.2 cases. There were N7851 female and N7448
male cases. Age adjusted rate per 100,000 patientswas 956.06/ 0.09 cases. There
were N1350 cases of diastolic heart failure i.e. an age adjusted rate of 71.48 /
2.24 cases (crude rate of 163.17 per 100,000). Most often length of stays ranged from
2 to 5 days. Analysis of residential zip codes indicates one suburb with a high
percentage of Hispanics and blacks with the highest reported cases (Waukegan
1557 cases). The overall age adjusted systolic CHF rate in Waukegan was
1313.35/ 36.47 cases per 100,000 which is significantly greater than the average
calculated rate for residents of Lake County [OR1.38 (1.30-1.47), P0.0001]
CONCLUSIONS: Lake County data suggest a higher rate of age-adjusted discharge
rate for CHF in parts of Lake county, IL, USA with a high % of Hispanic and black
population.
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OBJECTIVES: Hypertension is a public health problem worldwide, but the preva-
lence in Amassoma, which hosts the Niger Delta University, is not known. The
objective of the study was to investigate the prevalence of hypertension in the
locality and the extent of control in diagnosed cases. METHODS: Four hundred
adults selected through stratified sampling across the various compounds called
“AMA” and aged 20 years and above were included. It took place in between Feb-
ruary and May 2011.It involves interviewer administered questionnaires on demo-
graphics, predisposing factors and relevant medication history and measurement
of respondents’ blood pressure (BP) (on two separate occasions), weight and height.
The Body Mass Index (BMI) calculated and the data were appropriately analysed.
RESULTS:Majority of respondentswere female. Almost half of respondents (46.5%)
had their BMI above normal, 15.3% (61) of which falls within the obese region
(30.0kg/m2). Crude prevalence rate of hypertension ( BP of 140/90 mmHg)in the
community was 15.0% (60) out of which 13.8 % (55) were previously diagnosed. The
hypertension was that of Stage I (140-159/90-99mmHg) in 11.5% (46) and Stage II
(160/100 mmHg) in 3.5% (14). About half (51.0%) of previously diagnosed cases
(n55) were on any form of drug or the other. Another 23.5% had their BP in
pre-hypertensive stage (120-139/80-89mmHg). The prevalence rate among 40 years
and above was 10.5%. There was no statistically significant difference between
both sexes (2; p0.241), with 12.5% (n240) in females and 18.7% (n140) in male
respondents. The variation of BP among the various age groups was not significant
(p0.399; ANOVA). CONCLUSIONS: The prevalence of hypertension in Amassoma
community of Southern Ijaw, Bayelsa State is 15.0% with a pre-hypertension in
another 23.5% of the community. There is poor control of BP among previously
diagnosed hypertensive patients.
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OBJECTIVES: In this study we performed hypertension gap analysis for the resi-
dents of Lake county, IL based on the hospital discharge data collected between
2001- 2009.METHODS: The hospital discharge data between 2001-2009 for primary
diagnosis of HTN was analyzed. All patients ( 4 yr. to 85yr ) were categorized in
10 age groups and comparative analysis were performed. Cases for essential hy-
pertension were identified using ICD-9 codes . RESULTS: N 827,355 discharge
records were screened. Overall there were N1959 cases ( malignant 393; be-
nign17 and non-specific  1549 ) with the primary diagnosis of hypertension
reflecting a crude rate of 0.236%. consistent with a previous report by the state of IL
in 2004. There were N1249 female and N710 male cases, The age-adjusted rate
per 100,000 patients was 196.85 / 7.37 for females (crude rate of 248.77) and
236.41 / 10.92 cases in men ( crude rate of 218.27). For majority of patients the
length of stay were either 1 day (n744), 2 days (n567) or 3 days (n318) which is
comparable to IL data - an average of 2.6 days. Analysis of data based on residential
zip codes indicates 3 suburbs with a high percentage of Hispanics and blacks with
the highest reported cases( Waukegan 243 cases, Zion 102 cases, North Chi-
cago99 cases).Waukegan has greater than 50%hispanics ( 70%Mexican heritage).
The overall age-adjusted HTN rate in Waukegan was 279.2 / 19.11 cases per
100,000 which is significantly greater than the average calculated rate for either
males or females in the lake county [OR females1.42 (.64-.81), P.0001; OR-
males1.18 (.73-.98), P0.022] CONCLUSIONS: This data suggest a significantly
higher rate of age adjusted discharge rate for HTN in parts of Lake county, IL, USA
that have a high % of Hispanic and black population.
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OBJECTIVES: About 16,000 children suffer a cardiac arrest (CA) in the US each year.
Children having CA in an inpatient setting experience a lower death rate than
children having CA outside the hospital. The objectives of this study were to: 1.)
describe the inpatient CA pediatric population; 2.) determine the primary cause of
hospital admission for these patients; and 3.) determine whether the type of hos-
pital in which the patient was treated impacted survival post CA.METHODS: Dis-
charges for children aged 0-20 were selected from the Kids’ Inpatient Database
(KID) for the years 2003,2006,and 2009 if a primary or secondary diagnosis was
identified as ICD-9 code 427.5 (CA). Frequencies of discharges with CA were calcu-
lated and stratified by various patient and hospital characteristics, includingMajor
Diagnostic Code (MDC) to determine the primary cause for the hospital admission
and hospital type. Hospital type was classified by the National Association of Chil-
dren’s Hospitals and Related Institutions (NACHRI) to be a children’s hospital, a
children’s unit in a general hospital, or a non-children’s hospital. RESULTS: The
rate of death in pediatric hospitalizations declined from 66.46% in 2003 to 52.73% in
2009. The most common admission diagnoses involved the circulatory system
(about 27% each year), injuries from poison and toxic effects of drugs (about 10%
each year), and the respiratory system (16%, 18%, and 19%, for 2003, 2006, and 2009
respectively). Although the overall death rate decreased from 2003-2009, the rate of
decline was greater for both children’s hospitals and children’s units in general
hospitals. Whereas the rate declined from 66% to 57% for non-children’s hospitals
from 2003-2009, the rate declined from 64% to 51% for children’s hospitals.
CONCLUSIONS: The pediatric death rate is high in an inpatient setting. Between
the years 2003-2009, however,the death rate has declined, especially in pediatric
hospitals.
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OBJECTIVES: Recent US healthcare legislation highlights the need to assess insti-
tutional performance relative to regional or national norms. The study described
here introduces a simple and effective methodology for risk adjusted outcome
rates at the hospital level using observational data. It evaluates 4 regional hospitals
performance for inpatient PCI compared to all Premier hospitals. METHODS: A
total of 617,332 PCI patients from 324 hospitals between 2004 and 2009 were iden-
tified in the Premier Hospital Database. Clinical outcomeswere Clinically Apparent
Bleeding (CAB), defined by ICD-9 codes, and Inpatient Mortality (IM). Logistic mod-
els for each clinical outcome adjusted patient demographics, baseline comorbidity,
disease status, and hospital variables. Estimated patient level probabilities were
summed as the expected events for each hospital. Observed events divided by the
expected events produced anObserved to Expected Ratio (OER). OER 1 implies the
risk adjusted hospital event rate is higher than expected. RESULTS: The number of
PCI patients for hospitals 1through 4 were 1,737, 966, 990, and 309 respectively.
Observed CAB rates (%) were 4.4, 8.0, 3.8, and 8.7, compared to an overall rate of
5.4% for all Premier hospitals. The CAB OERs were 1.09, 1.75, 0.98, and 1.04. Unad-
justed IM rates (%) for hospitals 1 through 4 were 1.2, 1.6, 0.3, and 1.6. IM OERs were
0.86, 0.95, 0.40, and 1.02. Overall Premier IMwas 1.3%. Observed CAB for hospitals 2
and 4 were at least 48% higher than overall Premier. Post, however, risk adjust-
ment, hospital 2 remainedhighwhile hospital 4 decreased to 1.04, similar to overall
Premier. In contrast, the mortality OER for hospital 2 fell below the Premier bench-
mark despite its high observed rate. CONCLUSIONS: The OER provides a simple,
methodologically sound approach to review outcomes. It allows subpopulations to
have adjusted outcomes that can be compared to appropriate peer groups.
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